Close Menu

NEW YORK – CareDx reported on Monday that its preliminary revenues for the fourth quarter of 2019 are expected to be $35.7 million to $36.0 million, an increase of 52 percent to 53 percent compared to the $23.5 million in revenues reported in Q4 2018. Analysts expect the company to report $34.2 million in revenues for Q4.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.